Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
- Conditions
- B-cell Chronic Lymphocytic Leukemia
- Interventions
- Biological: B-CLL VaccineDrug: Lenalidomide
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 2
- Registration Number
- NCT01604031
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Thomas Kipps
- Target Recruit Count
- 11
- Registration Number
- NCT01600053
- Locations
- 🇺🇸
Moores UCSD Cancer Center, La Jolla, California, United States
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 194
- Registration Number
- NCT01593410
- Locations
- 🇨🇳
307 Hospital of Chinese PLA, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 38
- Registration Number
- NCT01583283
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01578954
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Maintenance Lenalidomide in Lymphoma
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT01575860
- Locations
- 🇺🇸
Jakub Svoboda, Philadelphia, Pennsylvania, United States
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaRelapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 722
- Registration Number
- NCT01564537
- Locations
- 🇺🇸
University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸West Contra Costa Healthcare District, Berkeley, California, United States
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT01562405
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hosptial, Boston, Massachusetts, United States
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 74
- Registration Number
- NCT01559935
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
- Conditions
- Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)
- Interventions
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 19
- Registration Number
- NCT01556035
- Locations
- 🇫🇷
CHU Amiens, Hôpital Sud, Amiens, France
🇫🇷CHRU de Montpellier Hôpital Saint-Eloi, Montpellier, France
🇫🇷Centre Léon Bérard, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.